DOI QR코드

DOI QR Code

Rhabdomyosarcoma - an Epidemiological and Histopathologic Study of 277 Cases from a Major Tertiary Care Center in Karachi, Pakistan

  • Ahmad, Zubair (Department of Pathology and Microbiology, Aga Khan University Hospital) ;
  • Din, Nasir Ud (Department of Pathology and Microbiology, Aga Khan University Hospital) ;
  • Ahmad, Arsalan (Department of Pathology and Microbiology, Aga Khan University Hospital) ;
  • Imran, Sheharbano (Department of Pathology and Microbiology, Aga Khan University Hospital) ;
  • Pervez, Shahid (Department of Pathology and Microbiology, Aga Khan University Hospital) ;
  • Ahmed, Rashida (Department of Pathology and Microbiology, Aga Khan University Hospital) ;
  • Kayani, Naila (Department of Pathology and Microbiology, Aga Khan University Hospital)
  • 발행 : 2015.02.25

초록

Aim: To present the epidemiologic data (age, gender, size etc) and histopathologic and immunohistochemical features of cases of rhabdomyosarcoma (RMS) reported in our department. Settings: Section of Histopathology, Department of Pathology and Microbiology, Aga Khan University Hospital, Karachi, Pakistan. Duration: All cases of RMS diagnosed between January 1, 2003 and December 31, 2012 were included in the study. Results: A total of 277 cases were included. Embryonal rhabdomyosarcoma (ERMS) was by far the dominant histologic type (87.4%) followed by alveolar type (ARMS)(9.4%). ERMS was much more common in males (64.0%)and over 65% of cases occurred in the first decade of life (over 90% in the first two decades). Head and neck region was commonest site for ERMS (46.7%), followed by the genitourinary system (16.1%). Over 65% cases of ARMS occurred in the extremities. Over 80% cases of ARMS occurred in the first 3 decades of life. Immunohistochemical staining for Desmin and MyoD1 was positive in 96.7% and 85.4% respectively. Conclusions: The epidemiologic data and microscopic findings in our patients are similar to international published data on rhabdomyosarcoma.

키워드

참고문헌

  1. Arndt CA, Stoner JA, Hawkins DS, et al (2009). Vincristine, Actinomycin and cyclophosphamide alternating with vincristine, topotecan and cyclophosphamide for intermediate risk rhabdomyosarcoma: children's oncology group study D9803. J ClinOncol, 27, 5182-8. https://doi.org/10.1200/JCO.2009.22.3768
  2. Bhurgri Y, Bhurgri A, Puri R, et al (2004). Rhabdomyosarcoma in Karachi 1998-2002. Asian Pac J Cancer Prev, 5, 284-90.
  3. Caillaud JM, et al (1989). Histopathologic classification of childhood rhabdomyosarcoma: a report from the international Society of Pediatric Oncology pathology panel. Med Pediatr Oncol, 17, 391-400. https://doi.org/10.1002/mpo.2950170508
  4. Cavazzana AO, et al (1992). Spindle cell rhabdomyosarcoma. A prognostically favourable variant of rhabdomyosarcoma. Am J Surg Pathol, 16, 229-35. https://doi.org/10.1097/00000478-199203000-00002
  5. Cessna MH, et al (2011). Are myogenin and Myo D1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics. Am J Surg Pathol, 25, 1150-7.
  6. Chiles MC, Parhaw DM, Qualman SJ, et al (2004). Sclerosing rhabdomyosarcoma in children and adolescents: a clinicopathologic review of 13 cases from the intergroup rhabdomyosarcoma study group and children's oncology group. Pediatr Dev Pathol, 7, 583-94. https://doi.org/10.1007/s10024-004-5058-x
  7. Gurney JG, Davis S, Severson RK, et al (1996). Trends in cancer incidence among children in the U.S. Cancer, 78, 532-41. https://doi.org/10.1002/(SICI)1097-0142(19960801)78:3<532::AID-CNCR22>3.0.CO;2-Z
  8. Gurney JG, Ross JA, Wall DA, et al (1997). Infant cancer in the U.S. histology specific incidence and trends, 1973 to 1992. J Pediatr Hematol Oncol, 19, 428-32. https://doi.org/10.1097/00043426-199709000-00004
  9. Harms D (1995). Alveolar rhabdomyosarcoma: a prognostically unfavourable rhabdomyosarcoma type and its necessary distinction from embryonal rhabdomyosarcoma. Curr Top Pathol, 89, 273-96. https://doi.org/10.1007/978-3-642-77289-4_14
  10. Hawkins WG, Hoos A, Antonescu CR, et al (2001). Clinicopathologic analysis of patients with adult rhabdomyosarcoma. Cancer, 91, 794-803. https://doi.org/10.1002/1097-0142(20010215)91:4<794::AID-CNCR1066>3.0.CO;2-Q
  11. Jo VY, Marino-Enriquez A, Flethcher CD (2011). Epithelioid rhabdomyosarcoma; clinicopathologic analysis of 16 cases of a morphologically distinct variant of rhabdomyosarcoma. Am J Surg Pathol, 35, 1523-30. https://doi.org/10.1097/PAS.0b013e31822e0907
  12. Joshi D anderson JR, et al (2004). Age is an independent prognostic factor in rhabdomyosarcoma: a report from the soft tissue sarcoma committee of the children's oncology group. Pediatr Blood Cancer, 42, 64-73. https://doi.org/10.1002/pbc.10441
  13. Liu CX, et al (2014). Compound HRAS/PIK3CA mutations in Chinese patients with alveolar rhabdomyosarcoma. Asian Pac J Cancer Prev, 15, 1771-4. https://doi.org/10.7314/APJCP.2014.15.4.1771
  14. Meyer WH, Spunt SL (2004). Soft tissue sarcomas of childhood. Cancer Treat Rev, 30, 269-80. https://doi.org/10.1016/j.ctrv.2003.11.001
  15. Missaoni N, et al (2010). Pediatric rhabdomyosarcoma in Tunisia. Asian Pac J Cancer Prev, 11, 1325-7.
  16. Molenaar WM, Oosterhuis JW, Oosterhuis AM, Ramaekers FC (1985). Mesenchymal and muscle specific intermediate filaments (vimentin and desmin) in relation to differentiation in childhood rhabdomyosarcoma. Hum Pathol, 16, 838-43. https://doi.org/10.1016/S0046-8177(85)80256-2
  17. Morotti RA, et al (2006). An immunhistochemical algorithm to facilitate diagnosis and subtyping of rhabdomyosarcoma; the children's oncology group experience. Am J Surg Pathol, 30, 962-8. https://doi.org/10.1097/00000478-200608000-00005
  18. Newton Jr WA, et al (1995). Classification of rhabdomyosarcomas and related sarcomas. Prognostic aspects and proposal for a new classification-an intergroup rhabdomyosarcoma study. Cancer, 76, 1073-85. https://doi.org/10.1002/1097-0142(19950915)76:6<1073::AID-CNCR2820760624>3.0.CO;2-L
  19. Ognjanovic S, Linabery AM, Charbonneau B, Ross JA (2009). Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005. Cancer, 115, 4218-26. https://doi.org/10.1002/cncr.24465
  20. Parkin DM, Stiller CA, Drager GJ, Bieber CA (1988).The international incidence of childhood cancer. Int J Cancer, 42, 511-20. https://doi.org/10.1002/ijc.2910420408
  21. Raney RB, Walterhouse DO, Meza JL, et al (2011). Results of the intergroup rhabdomyosarcoma study group D9602 protocol, using vincristine and dactinomysin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low risk embryonal rhabdomyosarcoma: a report from the soft tissue sarcoma committee of the children's oncology group. J Clin Oncol, 29, 1312-8. https://doi.org/10.1200/JCO.2010.30.4469
  22. Stock N, et al (2009). Adult-type rhabdomyosarcoma:analysis of 57 cases with clinicopathologic description, identification of 3 morphologic patterns and prognosis. Am J Surg Pathol, 33, 1850-9. https://doi.org/10.1097/PAS.0b013e3181be6209
  23. Sultan I, Qaddonmi I, Yaser S, Rodrigue-Galindo C, Ferrari A (2009). Comparing adult and pediatricrhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2600 patients. J Clin Oncol, 27, 3391-7. https://doi.org/10.1200/JCO.2008.19.7483
  24. WHO Classification of Tumors of Soft Tissue and Bone (2013). Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F eds. 4th Edition. International Agency for Research on Cancer (IARC), Lyon, 123-36.
  25. Yasuda T, et al (2009). Alveolar rhabdomyosarcoma of the head and neck region in older adults: genetic characterization and review of the literature. Human Pathol, 40, 341-8. https://doi.org/10.1016/j.humpath.2008.08.006